Axsome Therapeutics Reports Q3 Revenue Beat and Improved EPS
Axsome Therapeutics (AXSM) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.25, which outperformed estimates by $0.38, and recorded revenue of $259.7 million, representing a 51.9% increase year-over-year. The strong top-line growth was driven largely by the performance of its product Auvelity. Following the earnings release, Axsome shares saw an immediate positive reaction, rising approximately 2.5% in after-hours trading as investors reacted to the revenue beat and significant year-over-year expansion.
Tickers: $AXSM
Topics: biotechnology earnings beat financial results revenue growth
Read the full article at Seeking Alpha
Part of the story Cogent Communications Reports Q3 2026 Results with Improved EBITDA Margins and Wavelength Growth (22 articles)